CHELSEA MILLER: Open Payments
NPI 1043659196 · MERIDIAN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$687 in 39 payments from 11 companies in 2025. Trend: 2023 $545 · 2024 $757 · 2025 $687
Food & beverage: $687
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 17 | $294 |
| Regeneron Healthcare Solutions, Inc. | 7 | $151 |
| ABBVIE INC. | 3 | $63 |
| Organon LLC | 5 | $49 |
| UCB, Inc. | 1 | $23 |
| Galderma Laboratories, L.P. | 1 | $21 |
| Janssen Biotech, Inc. | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| Arcutis Biotherapeutics, Inc. | 1 | $17 |
| LEO Pharma Inc. | 1 | $16 |
Products named: DUPIXENT, COSENTYX, Rhapsido, SKYRIZI, XOLAIR, VTAMA, Bimzelx, NEMLUVIO.
Industry payments across ID — which companies pay providers there.
